A controversial bill to lower costs of diabetes drugs was vetoed on Friday by the Nevada governor, the latest of many efforts by state legislators to fail to contain rising medicine prices.
The bill would have required drug makers to report pricing histories, disclose costs, notify state officials and insurers in advance of price hikes above inflation, and report rebates paid to pharmacy benefit managers, the middlemen that negotiate favorable insurance coverage.
About the Author Reprints
May I observe that the idea of ‘stockpiling’ cold-chain drugs with a limited expiration date strikes me as a bit weak. Others may differ.
We must regard our government, at every level, as the enemy of the people. There are no heroes, no champions of the people in the governing body, only mercenaries hired by big money, only self aggrandizers intent only on reelection. We must, we must, serve notice.